Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease with a variable response to
treatment. Although the majority of AML patients achieve a complete morphologic remission after induction chemotherapy, relapse remains the major cause of death in AML. The objective of this thesis was to further refine risk classification at diagnosis and investigate the value of molecular residual disease detection by next-generation sequencing during treatment, with the ultimate goal to improve relapse prediction in AML.
treatment. Although the majority of AML patients achieve a complete morphologic remission after induction chemotherapy, relapse remains the major cause of death in AML. The objective of this thesis was to further refine risk classification at diagnosis and investigate the value of molecular residual disease detection by next-generation sequencing during treatment, with the ultimate goal to improve relapse prediction in AML.
| Original language | English |
|---|---|
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 15 Sept 2023 |
| Place of Publication | Rotterdam |
| Print ISBNs | 978-94-6361-889-2 |
| Publication status | Published - 15 Sept 2023 |